Literature DB >> 16370403

Management of Staphylococcus aureus infections.

David M Bamberger1, Sarah E Boyd.   

Abstract

Because of high incidence, morbidity, and antimicrobial resistance, Staphylococcus aureus infections are a growing concern for family physicians. Strains of S. aureus that are resistant to vancomycin are now recognized. Increasing incidence of unrecognized community-acquired methicillin-resistant S. aureus infections pose a high risk for morbidity and mortality. Although the incidence of complex S. aureus infections is rising, new antimicrobial agents, including daptomycin and linezolid, are available as treatment. S. aureus is a common pathogen in skin, soft-tissue, catheter-related, bone, joint, pulmonary, and central nervous system infections. S. aureus bacteremias are particularly problematic because of the high incidence of associated complicated infections, including infective endocarditis. Adherence to precautions recommended by the Centers for Disease Control and Prevention, especially handwashing, is suboptimal.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16370403

Source DB:  PubMed          Journal:  Am Fam Physician        ISSN: 0002-838X            Impact factor:   3.292


  18 in total

1.  Intra- and extracellular activities of dicloxacillin and linezolid against a clinical Staphylococcus aureus strain with a small-colony-variant phenotype in an in vitro model of THP-1 macrophages and an in vivo mouse peritonitis model.

Authors:  Anne Sandberg; Sandrine Lemaire; Françoise Van Bambeke; Paul M Tulkens; Diarmaid Hughes; Christof von Eiff; Niels Frimodt-Møller
Journal:  Antimicrob Agents Chemother       Date:  2011-01-31       Impact factor: 5.191

2.  Methicillin-resistant Staphylococcus aureus in surgical patients: identification of high-risk populations for the development of targeted screening programmes.

Authors:  Stephanie Fraser; Richard R Brady; Catriona Graham; Simon Paterson-Brown; Alan P Gibb
Journal:  Ann R Coll Surg Engl       Date:  2010-05       Impact factor: 1.891

Review 3.  β-Lactams and β-Lactamase Inhibitors: An Overview.

Authors:  Karen Bush; Patricia A Bradford
Journal:  Cold Spring Harb Perspect Med       Date:  2016-08-01       Impact factor: 6.915

4.  A high-throughput screen for antibiotic drug discovery.

Authors:  Thomas C Scanlon; Sarah M Dostal; Karl E Griswold
Journal:  Biotechnol Bioeng       Date:  2013-08-29       Impact factor: 4.530

5.  Cefazolin high-inoculum effect in methicillin-susceptible Staphylococcus aureus from South American hospitals.

Authors:  Sandra Rincón; Jinnethe Reyes; Lina Paola Carvajal; Natalia Rojas; Fabián Cortés; Diana Panesso; Manuel Guzmán; Jeannete Zurita; Javier A Adachi; Barbara E Murray; Esteban C Nannini; Cesar A Arias
Journal:  J Antimicrob Chemother       Date:  2013-06-21       Impact factor: 5.790

6.  Intra- and extracellular activities of dicloxacillin against Staphylococcus aureus in vivo and in vitro.

Authors:  Anne Sandberg; Klaus Skovbo Jensen; Pierre Baudoux; Françoise Van Bambeke; Paul M Tulkens; Niels Frimodt-Møller
Journal:  Antimicrob Agents Chemother       Date:  2010-03-22       Impact factor: 5.191

7.  Characteristics of cefazolin inoculum effect-positive methicillin-susceptible staphylococcus aureus infection in a multicentre bacteraemia cohort.

Authors:  K-H Song; S-I Jung; S Lee; S Park; S M Kiem; S H Lee; Y G Kwak; Y K Kim; H-C Jang; Y-S Kim; H-I Kim; C J Kim; K-H Park; N J Kim; M-D Oh; H B Kim
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-10-06       Impact factor: 3.267

8.  Multiple ligands of von Willebrand factor-binding protein (vWbp) promote Staphylococcus aureus clot formation in human plasma.

Authors:  Lena Thomer; Olaf Schneewind; Dominique Missiakas
Journal:  J Biol Chem       Date:  2013-08-19       Impact factor: 5.157

9.  Intracellular activity of antibiotics against Staphylococcus aureus in a mouse peritonitis model.

Authors:  Anne Sandberg; Jonas H R Hessler; Robert L Skov; Jens Blom; Niels Frimodt-Møller
Journal:  Antimicrob Agents Chemother       Date:  2009-02-17       Impact factor: 5.191

10.  Evaluation of apramycin activity against methicillin-resistant, methicillin-sensitive, and vancomycin-intermediate Staphylococcus aureus clinical isolates.

Authors:  Katherine A Truelson; Thea Brennan-Krohn; Kenneth P Smith; James E Kirby
Journal:  Diagn Microbiol Infect Dis       Date:  2018-05-29       Impact factor: 2.803

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.